Kepler Cheuvreux Suisse SA Takes Position in Boston Scientific Corporation $BSX

Kepler Cheuvreux Suisse SA acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,109 shares of the medical equipment provider’s stock, valued at approximately $1,074,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. FWL Investment Management LLC bought a new position in Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Bangor Savings Bank raised its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. Finally, Board of the Pension Protection Fund bought a new stake in shares of Boston Scientific in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 9,800 shares of company stock valued at $554,012 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BSX has been the subject of a number of analyst reports. Raymond James Financial restated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Stifel Nicolaus dropped their target price on Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. Jefferies Financial Group cut their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Mizuho reduced their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Stock Down 0.1%

BSX opened at $45.09 on Friday. The stock’s 50 day moving average price is $50.99 and its 200 day moving average price is $69.43. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market cap of $67.01 billion, a P/E ratio of 18.86, a P/E/G ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $42.25 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.